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Abstract
Background: Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in
intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections
with limited or no adequate therapeutic options. A survey was conducted to assess the intensive care physicians’
perception of the AMR situation in the European Union/European Economic Area (EU/EEA).
Methods: Between May and July 2017, physicians working in European ICUs were invited to complete an online
questionnaire hosted by the European Society of Intensive Care Medicine. The survey included 20 questions on
hospital and ICU characteristics, frequency of infections with multidrug-resistant (MDR) bacteria and relevance of
AMR in the respondent’s ICU, management of antimicrobial treatment as well as the use of last-line antibiotics in
the six months preceding the survey. For the analysis of regional differences, EU/EEA countries were grouped into
the four sub-regions of Eastern, Northern, Southern and Western Europe.
Results: Overall, 1062 responses from four European sub-regions were analysed. Infections with MDR bacteria in
their ICU were rated as a major problem by 257 (24.2%), moderate problem by 360 (33.9%) and minor problem by
391 (36.8%) respondents. Third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently
encountered MDR bacteria followed by, in order of decreasing frequency, meticillin-resistant Staphylococcus aureus,
carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and vancomycin-resistant
enterococci. Perception of the relevance of the AMR problem and the frequency of specific MDR bacteria varied by
European sub-region. Bacteria resistant to all or almost all available antibiotics were encountered by 132 (12.4%)
respondents. Many physicians reported not having access to specific last-line antibiotics.
Conclusions: The percentage of European ICU physicians perceiving AMR as a substantial problem in their ICU is
high with variation by sub-region in line with epidemiological studies. The reports of bacteria resistant to almost all
available antibiotics and the limited availability of last-line antibiotics in ICUs in the EU/EEA are of concern.
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Background
Antimicrobial resistance (AMR) is a threat to public
health and compromises the treatment of infected pa-
tients, in particular the treatment of the most severely ill
patients. Intensive care units (ICUs) are often described as
the epicenter of AMR and intensive care physicians in
Europe are increasingly facing patients infected by bacteria
for which limited or no adequate therapeutic options are
available [1]. The use of last-line antibiotics has been in-
creasing, including in particular the use of colistin in
Southern and Eastern European countries as described by
the European Surveillance of Antimicrobial Consumption
Network (ESAC-Net) [2]. Only a few new antibiotics have
been marketed in recent years and they are not always
available for use in ICUs in European Union/European
Economic Area (EU/EAA) countries [3].
ARISE (Antimicrobial Resistance in ICU: a Survey in
Europe) is a survey of European ICU physicians with
respect to their perception of and experience due to infec-
tions caused by antibiotic-resistant bacteria. ARISE follows
a first survey conducted in 2009 [4] among the members
of the European Society of Intensive Care Medicine
(ESICM). Since 2009, the AMR situation in Europe has
worsened considerably with, for example, increased pro-
portions of third-generation cephalosporin, fluoroquino-
lone and carbapenem resistance in invasive Escherichia
coli and Klebsiella pneumoniae isolates, even if there has
been a stabilization of resistance proportions in recent
years [5, 6]. Multiple factors may contribute to the spread
of AMR in European countries including cross-border
transfer of patients carrying MDR bacteria, transmission
of high-risk bacterial clones in and between hospitals and
other healthcare settings, overuse and misuse of anti-
microbial agents and varying infection control practices
and staffing [7–10]. A second survey was therefore con-
ducted in 2017 among physicians working in European
ICUs with the aim to determine their current perception
of infections due to antibiotic-resistant bacteria and the
use of last-line antibiotics.
Methods
The survey was designed in collaboration with the Euro-
pean Centre for Disease Prevention and Control (ECDC)
and reviewed by members of the Infection Section of
ESICM. The survey was endorsed by ESICM through its
European Critical Care Network in May 2017. It was
posted on the ESICM website in the section “Survey of the
month” on 19 May 2017 and was closed on 17 July 2017.
Inclusion criteria
Eligible participants were a convenience sample of physi-
cians in charge of prescribing antibiotics to ICU patients
and working in ICUs in the EU/EEA. Physicians outside
the EU/EEA could also respond, but their answers were
not included in the analysis.
Dissemination strategy
An invitation to participate was transmitted through
ESICM, ECDC and national intensive care societies to
their networks via email or web postings. The survey was
also promoted via Twitter messages and Facebook posts.
Survey description
Questions on the characteristics of respondents and
management of antimicrobial treatment
The ARISE survey included 20 questions. The first ques-
tions inquired about the characteristics of the hospital and
the ICU in which the respondents worked, as well as their
training in intensive care medicine and included the
percentage of working time dedicated to the ICU, the fre-
quency of antibiotic prescribing, and the perception of the
extent of the problem of AMR. Existence of guidelines on
antimicrobial treatment and their origin as well as the
availability of local AMR statistics were also explored.
Questions on experience with infections due to MDR
bacteria
The survey included questions about the number of
patients cared for, during the preceding six months, with
eight antibiotic-bacteria combinations related to multidrug-
resistant (MDR) bacteria: three combinations included
Gram-positive bacteria (meticillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus spp.
(VRE), penicillin-resistant Streptococcus pneumoniae)
and four combinations included Gram-negative bacteria
(third-generation cephalosporin-resistant Enterobacte-
riaceae, carbapenem-resistant Enterobacteriaceae,
carbapenem-resistant Pseudomonas aeruginosa and
carbapenem-resistant Acinetobacter spp.). Participants
were invited to evaluate the frequency of encounter
with patients with the above mentioned MDR bacteria
according to a semi-quantitative scale: encountered
very often (> 30 patients), often (11–30 patients), some-
times (3–10 patients), rarely (1–2 patients) and never.
Bacteria totally or almost totally resistant to available
antibiotics could also be reported.
Questions on experience with use of last-line antibiotics
The same approach as for MDR bacteria was applied to
the last-line antibiotics used in the participants’ ICUs. A
closed list of eight antibiotics (linezolid, daptomycin, fos-
fomycin, colistin, tigecycline, ceftolozane-tazobactam,
ceftazidime-avibactam, and temocillin) was proposed for
a similar evaluation of the frequency of prescription by
the respondent. The possibility of declaring the unavail-
ability of the above mentioned antibiotics due to either
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local unavailability (in the hospital/unit) or unavailability
in the country was included.
Questions on priorities for improvement of the AMR
situation in ICUs
Finally, participants were also asked to rank six options
having a potential impact on the AMR situation in their
ICU by order of priority from 1 to 6, with the option
with the lowest number being the highest-ranked option.
The options were: “faster/better microbiological diagnos-
tics“, “opportunities for training/education of clinicians
for better use of existing antibiotics”, “more resources
for infection control“, “more locally adapted guidelines”,
“new antibiotics”, and “more opportunity for specialist
consultation”. For each option, the ranks were then
added and divided by the number of respondents. The
original questionnaire is available as supplementary ma-
terial in Additional file 1.
Statistical analysis
Statistical analyses were predefined in the statistical ana-
lysis plan. EU/EEA countries were grouped in four sub-
regions according to the classification used by the Statis-
tics Division of the United Nations: Eastern Europe
(Bulgaria, Czech Republic, Hungary, Poland, Romania,
Slovakia), Northern Europe (Denmark, Estonia, Finland,
Iceland, Ireland, Latvia, Lithuania, Norway, Sweden,
United Kingdom), Southern Europe (Croatia, Cyprus,
Greece, Italy, Malta, Portugal, Slovenia, Spain) and
Western Europe (Austria, Belgium, France, Germany,
Liechtenstein, Luxembourg, the Netherlands) [11].
Descriptive statistics were used to summarize charac-
teristics of respondents within the four European sub-
regions. The data were compared using the Pearson’s
Chi-squared test and the Kruskal-Wallis test.
To improve understanding of factors associated with
the perception of the magnitude of the AMR problem by
physicians, a multivariate model was constructed includ-
ing region, type of hospital, number of beds, number of
admissions, existence of protocols and access to guide-
lines as independent variables. All variables were se-
lected based on their significance at a threshold of p <
0.05. The multivariate analysis was performed using a
cumulative logistic regression with proportional odds
(and 95% confidence intervals). Variables for the model
were selected following forward regression and valid-
ation of the global model was performed using the likeli-
hood ratio test. All analyses were conducted using the R
software version 3.4.1.
Results
Overall, 1141 responses were received, of which 1062 were
from physicians working in the EU/EEA and therefore eli-
gible for analysis (Table 1). Nearly half of the responses
came from the Western European sub-region, followed by
the Southern, Northern and Eastern European sub-region
(Table 1). A complete list of the number of respondents
by country is available in Additional file 2.
Characteristics of respondents
Respondents were working more frequently in univer-
sity/teaching hospitals than in general hospitals and
most frequently in mixed medical-surgical ICUs (Table
1). The majority of respondents were ICU specialists or
physicians in training for this specialty. The responding
physicians had been for a median of 17 years in clinical
practice and the median percentage of their working
time dedicated to intensive care was high (80.0%). The
majority of respondents declared that they prescribed
antibiotics often or commonly. There were significant
regional differences for most hospital, ICU and physician
characteristics (Table 1).
Management of antimicrobial treatment
More than half of the respondents stated that they con-
sulted an infectious disease specialist in case of difficult-
to-treat infections (Table 1). Almost three-quarters of
respondents reported having protocols for empiric treat-
ment of infections in their ICU. Protocols and guidelines
for antibiotic treatment were ICU-specific in about half
of the cases. Slightly more than half of the respondents
received regular reports of AMR statistics for their ICU.
There were regional differences in the availability of pro-
tocols for empiric treatment and AMR statistics as well
as infectious disease specialist consultations. Infections
with MDR bacteria in their ICU were rated as a major
problem by 257 (24.2%), a moderate problem by 360
(33.9%) and a minor problem by 391 (36.8%) respon-
dents. The ranking of infections with MDR bacteria dif-
fered by region and they were more often considered a
major problem by respondents in countries of the East-
ern and Southern European sub-regions compared to
the Northern and Western sub-regions.
Experience with infections due to MDR bacteria
Third-generation cephalosporin-resistant Enterobacte-
riaceae were the most frequently reported MDR bac-
teria followed by, in order of decreasing frequency,
MRSA, carbapenem-resistant Enterobacteriaceae,
carbapenem-resistant Pseudomonas aeruginosa and
VRE (Fig. 1). Bacteria resistant to all or almost all
available antibiotics were reported by 132 (12.4%) re-
spondents. Percentages of ICU physicians having cared
for three or more patients with MDR bacteria in the
past six months are presented by sub-region in Fig. 2
(denominator: 858 respondents after excluding miss-
ing or not explicit answers).
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Table 1 Characteristics of ARISE survey participants from the EU/EEA, 2017 (n = 1062)
European sub-region Total P-value
Eastern Northern Southern Western
Total replies [n (%)]a 94 (8.9) 233 (21.9) 248 (23.4) 487 (45.9) 1062 (100)
Hospital and ICU characteristics
Type of hospital [n, (%)]b
General hospital 35 (37.2) 100 (42.9) 124 (50.0) 192 (39.4) 451 (42.5) < 0.05
University/teaching 59 (62.8) 133 (57.1) 124 (50.0) 295 (60.6) 611 (57.5)
Type of ICU [n (%)]b
Medical ICU 10 (10.6) 6 (2.6) 22 (8.9) 53 (10.9) 91 (8.6) < 0.001
Surgical ICU 5 (5.3) 5 (2.1) 12 (4.8) 112 (23.0) 134 (12.6)
Mixed ICU 66 (70.2) 197 (84.5) 184 (74.2) 289 (59.3) 736 (69.3)
Other ICU 13 (13.8) 25 (10.7) 30 (12.1) 33 (6.8) 101 (9.5)
Number of beds in the ICU [Median (IQR)]
10 (6–13.5) 12 (8–20) 10 (8–15) 14 (10–20) 12 (8–18) < 0.001
Number of yearly ICU admissions [n (%)]b
≤ 300 29 (30.9) 15 (6.4) 57 (23.0) 25 (5.1) 126 (11.9) < 0.001
301–600 44 (46.8) 62 (26.6) 101 (40.7) 160 (32.9) 367 (34.6)
601–1200 13 (13.8) 101 (43.3) 65 (25.8) 190 (39.0) 368 (34.7)
> 1200 5 (5.3) 53 (22.7) 22 (8.9) 105 (21.6) 185 (17.4)
Missing 3 (3.2) 2 (0.9) 4 (1.6) 7 (1.4) 16 (1.5)
Characteristics of participating ICU physicians
Training status [n (%)]b
ICU specialist 78 (83.0) 178 (76.4) 208 (83.9) 386 (79.3) 850 (80.0) < 0.05
Medical specialist 1 (1.1) 5 (2.1) 13 (5.2) 25 (5.1) 44 (4.1)
Surgery specialist 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.4) 2 (0.2)
In training for ICU specialist 9 (9.6) 35 (15.0) 16 (6.5) 40 (8.2) 100 (9.4)
Other 1 (1.1) 7 (3.0) 0 (0.0) 4 (0.8) 12 (1.1)
Missing 5 (5.3) 8 (3.4) 11 (4.4) 30 (6.2) 54 (5.1)
Years of clinical practice in ICU [Median (IQR)]
20 (11.25–33.5) 15 (8–26) 15 (8–26) 18 (8–35) 17 (8–32.75) NS
Percentage of time dedicated to ICU [Median (IQR)]
61 (51–83.5) 61 (51–81) 96 (71–100) 81 (51–100) 80 (51–100) < 0.001
Perception of MDR bacteria [n (%)]b
Minor problem 17 (18.1) 115 (49.4) 63 (25.4) 196 (40.2) 391 (36.8) < 0.001
Moderate problem 34 (36.2) 79 (33.9) 80 (32.3) 167 (34.3) 360 (33.9)
Major problem 38 (40.4) 31 (13.3) 94 (37.9) 94 (19.3) 257 (24.2)
Missing 5 (5.3) 8 (3.4) 11 (4.4) 30 (6.2) 54 (5.1)
Antibiotic therapy prescription [n (%)]b
Commonly 25 (26.6) 60 (25.8) 84 (33.9) 179 (36.8) 348 (32.8) NS
Often 55 (58.5) 141 (60.5) 140 (56.5) 254 (52.2) 590 (55.6)
Rarely 14 (14.9) 32 (13.7) 24 (9.7) 54 (11.1) 124 (11.7)
Management of antimicrobial treatment
External specialist consultation in case of resistant or difficult to treat infections [n (%)]b
Infectious disease specialist 18 (19.1) 91 (39.1) 140 (56.5) 306 (62.8) 555 (52.3) < 0.001
Other external specialists 62 (66.0) 133 (57.1) 41 (16.5) 115 (23.6) 351 (33.1)
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Experience with use of last-line antibiotics
Linezolid, colistin, tigecycline and daptomycin were the
most frequently prescribed last-line antibiotics (Fig. 3).
Many respondents stated that specific last-line antibi-
otics were not available in their ICU. Unavailability was
most frequently the case for an old antibiotic such as
temocillin, but the recently marketed antibiotic-beta-
lactamase inhibitor combinations such as ceftolozane-
tazobactam and ceftazidime-avibactam were also often
not available.
Priorities for improvement of the AMR situation in ICUs
Among six proposed options for improvement of the
AMR situation in their ICU, respondents preferred “fas-
ter/better microbiological diagnostic methods” with an
adjusted score (AS) of 2.3, followed by “training/educa-
tion of clinicians for better use of antibiotics” (AS = 3.0)
and “more resources for infection control” (AS = 3.4).
“More locally adapted guidelines” (AS = 3.8), “new anti-
biotics” (AS = 3.9) and “more opportunity for specialist
consultation” (AS = 4.1) were considered as less pre-
ferred options. Analysis by European sub-region (data
not shown) showed a difference in preferences: “faster/
better diagnostic methods” was always the highest
ranked option in all four European sub-regions, while
“more opportunity for specialist consultation” was classi-
fied as the least preferred option in the Southern and
Western sub-regions. The need for “new antibiotics” was
not classified as the preferred option in any region and
was the least preferred option in respondents from the
Eastern region.
Multivariate analysis
The main factor significantly associated with a higher
ranking of the AMR problem was the sub-region of ori-
gin of the respondent (Table 2). Other significant factors
were number of yearly admissions between 601 and
1200 patients, the “other” type of ICU and lack of avail-
ability of protocols for empiric treatment in the ICU.
Discussion
This survey was completed by 1062 ICU physicians from
almost all EU/EEA countries and a majority reported
having a moderate to major problem with MDR bacteria
in their ICU. ICUs are particularly exposed to AMR.
This is due to the specific population of patients cared
for in ICUs that accumulate factors known to increase
the AMR risk as ICUs combine a high frequency of
Table 1 Characteristics of ARISE survey participants from the EU/EEA, 2017 (n = 1062) (Continued)
European sub-region Total P-value
Eastern Northern Southern Western
No consultation of external specialists 9 (9.6) 1 (0.4) 53 (21.4) 32 (6.6) 95 (8.9)
Missing/Do not know 5 (5.3) 8 (3.4) 14 (5.6) 34 (7.0) 61 (5.7)
Availability of protocols for empiric treatment in the ICU [n (%)]b
Yes 61 (64.9) 217 (93.1) 175 (70.6) 311 (63.9) 764 (71.9) < 0.001
No 28 (29.8) 6 (2.6) 58 (23.4) 138 (28.3) 230 (21.7)
Do not know 0 (0.0) 1 (0.4) 2 (0.8) 5 (1.0) 8 (0.8)
Missing 5 (5.3) 9 (3.9) 13 (5.2) 33 (6.8) 60 (5.6)
Type of guidelines/protocols/recommendations used for antimicrobial treatment [n (%)]b
ICU-specific 48 (51.1) 117 (50.2) 118 (47.6) 236 (48.5) 519 (48.9) NS
Other (hospital-specific, national or international) 29 (30.9) 91 (39.1) 84 (33.9) 155 (31.8) 359 (33.8)
None of the above 3 (3.2) 0 (0.0) 5 (2.0) 13 (2.7) 21 (2.0)
Do not know 2 (2.1) 1 (0.4) 1 (0.4) 3 (0.6) 7 (0.7)
Missing 12 (12.8) 24 (10.3) 40 (16.1) 80 (16.4) 156 (14.7)
Availability of resistance statistics for the ICU [n (%)]b
Regularly 58 (61.7) 111 (47.6) 142 (57.3) 261 (53.6) 572 (53.9) < 0.001
Irregularly 15 (16.0) 51 (21.9) 46 (18.5) 84 (17.2) 196 (18.5)
Not at all 7 (7.4) 18 (7.7) 15 (6.0) 36 (7.4) 76 (7.2)
Do not know 2 (2.1) 29 (12.4) 5 (2.0) 28 (5.7) 64 (6.0)
Missing 12 (12.8) 24 (10.3) 40 (16.1) 78 (16.0) 154 (14.5)
EU/EEA European Union/European Economic Area; ICU Intensive Care Unit; n number; IQR interquartile range; MDR Multi-drug resistance
aPercentage of all respondents
bPercentage of respondents by European region
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patients under antimicrobial treatment, a high intensity
of care with numerous invasive devices, and a concentra-
tion of severely ill patients with multiple previous hos-
pital stays and previous exposures to antibiotics [12].
The substantial proportion (12.4%) of ICU physicians
who reported that they had, during the preceding six
months, at least one patient with an infection caused by
a bacterium resistant to all or almost all antibiotics avail-
able in their ICU is of concern. This is an indication that
ICU physicians are already encountering situations
where options for effective treatment of infections are
very limited.
We analyzed the results by European sub-region to
take into account that the epidemiology of AMR as de-
scribed, for example, in the European Antimicrobial Re-
sistance Surveillance-Network (EARS-Net) reports [5],
and of antibiotic consumption as reported from ESAC-
Net [2] are largely heterogeneous in the EU/EEA. In
2016, EARS-Net reported a wide variation in AMR de-
pending on the bacterial species and the geographical re-
gion with higher percentages of AMR being reported by
countries in Southern and Eastern Europe. Our multi-
variate analysis of factors influencing the perception of
AMR confirmed the role of the European sub-region,
with ICU physicians in Eastern and Southern sub-
regions more frequently ranking MDR bacteria in their
ICU as a major problem. The other factors significantly
associated, in the multivariate analysis, with a higher
ranking of perception of AMR as a problem were related
to (a) the number of admissions and the type of ICU,
which are likely proxies for patient populations with dif-
ferent risks for infection with MDR bacteria, and (b) the
lack of protocols for empiric treatment, which might be
a sign of the absence of antibiotic stewardship activities
that could improve antibiotic prescribing and control of
MDR bacteria.
The EARS-Net report also highlighted a high level of
resistance to third-generation cephalosporins in Entero-
bacteriaceae which was reported in our survey as the
most frequently encountered type of MDR bacteria in
ICUs in the EU/EEA. Our survey also showed that
MRSA, despite a decline described in the recent years, is
still a problem in ICUs in the EU/EEA. Knowledge of
the local resistance situation is beneficial for the correct
choice of empiric antibiotic treatment [13]; however,
regular resistance statistics were only available in 53.9%
of respondents’ ICUs highlighting an important gap.
Responses regarding the use of last-line antibiotics
highlighted two important issues. Firstly, it confirmed the
lack of availability of older antibiotics in several EU/EEA
Fig. 1 Percentage of ARISE survey participants from the EU/EEA who reported having encountered patients with infections caused by selected
antibiotic-resistant bacteria during the past six months prior to the survey (n = number of responses for each bacterium)
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countries, as already raised by other studies [14, 15]. In
particular, colistin and temocillin were not available in
all EU/EEA countries [15, 16]. Secondly, our study
showed that the recently approved cephalosporin-beta-
lactamase inhibitor combinations targeting infections
with resistant Gram-negative bacteria: ceftolozane-
tazobactam and ceftazidime-avibactam, that received
marketing authorization valid throughout the European
Union in 2015 and 2016, respectively [17, 18], were not
always available in ICUs in EU/EEA countries. How-
ever, we were not able to differentiate between non-
availability of these antibiotics at national level or at
hospital level (e.g. because of cost or organizational rea-
sons). We also did not assess whether availability meant
rapid availability from the pharmacy or whether last-
line antibiotics had to be ordered from other providers
or countries with a delay that may impact appropriate
management of severely ill ICU patients. Many respon-
dents mentioned carbapenems in the category ‘other’
last-line antibiotics (data not shown), although they
were not included in our list of proposed last-line
antibiotics. This is an indication that carbapenems are
still considered as last-line antibiotics by many ICU
physicians in the EU/EEA.
A previous survey designed by ECDC, the European
Medicines Agency and ESICM among European intensive
care physicians with partially comparable, but not identi-
cal questions and only 95 respondents was published in
2009 [4]. Some results were similar in both surveys. For
example, MRSA and third-generation cephalosporin-re-
sistant Enterobacteriaceae were the most frequently re-
ported MDR bacteria in 2009 and in 2017. However,
there were differences in the scale used to measure the
perception of AMR, which prevents more detailed com-
parisons. In 2009, 50 (53%) respondents declared hav-
ing treated at least one patient with a bacterium totally
or almost totally resistant to available antibiotics during
the preceding six months, which is a higher percentage
than the result of the 2017 survey (12.4%). This might
be explained by the much lower number of respondents
and possible selection bias of these respondents in 2009
as well as possibly by a changing perception, among
Fig. 2 Percentage of ARISE survey participants from the EU/EEA who reported having encountered at least three patients with infections caused
by selected antibiotic-resistant bacteria during the past six months, by European region (n = 858)
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ICU physicians, of what constitutes “totally or almost
totally resistant” and should therefore be interpreted
with caution.
To our knowledge, similar European-wide surveys
have not recently been performed among ICU physi-
cians. A survey with the same target group, but focusing
on the concept of “salvage treatment” and indications
for and dosing of specific antibiotics has been conducted
by the ESCMID study group for critically ill patients
[19]. Other surveys have been conducted in different
physician populations or countries, including medical
residents of two university hospitals in France and
Scotland who were not always working in ICUs or in the
position to make decisions about antibiotic treatment
[20], physicians of 16 ICUs in the United States with a
focus on only Gram-negative MDR bacteria [21], and
physicians of only one European country, such as Italy
(175 Italian ICUs) [22] or Spain (114 paediatric ICU
physicians) [23]. One global survey was investigating
specifically the use of polymyxins [24]. Another global
survey was conducted among 129 global experts in in-
fections in critically ill patients, among them also 40
European intensivists, as part of development of a global
priority pathogen list specific for critical care [25]. Two
additional surveys that have been directed specifically to
ICU physicians with an important fraction of European
respondents investigated the prevention of ventilator-
associated pneumonia [26] and central line-associated
bloodstream infections [27], but not AMR and anti-
microbial use.
Our final question was about ranking options that
would have an impact on the AMR in the respondent’s
ICU. The preferred option was “faster/better microbio-
logical diagnostic tools”. This is not surprising in the
ICU context where the timely replacement of an empiric
antibiotic regimen with targeted treatment is of utmost
importance. New diagnostic tests are under develop-
ment, but there might be barriers to their use, often re-
lated to costs [28]. Furthermore, the correct use of these
new tests is important and, as stated by Messacar et al.
[29], diagnostic stewardship is required to direct the ap-
propriate tests to the right patient. “Opportunities for
training/education of clinicians for better use of existing
antibiotics” was the option ranked second by the respon-
dents, while “new antibiotics” was only ranked fifth sug-
gesting that ICU physicians have more trust in antibiotic
stewardship and better targeted use of existing antibi-
otics than in new antibiotics that might possibly become
Fig. 3 Percentage of ARISE survey participants from the EU/EEA who reported having used the antibiotics listed in the last-line antibiotics list
during the past six months (n = number of responses for each antibiotic)
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Table 2 Multivariate analysis of factors associated with a higher ranking of perception of AMR as a problem among ARISE
participants from the EU/EEA
Characteristics Univariate analysis Multivariate analysis
Odds Ratio 95% CI P-value Adjusted Odds Ratio 95% CI P-value
European sub-region
Western 1 1
Eastern 2.95 1.93–4.53 < 0.001 3.09 1.94–4.92 < 0.001
Northern 0.70 0.51–0.94 < 0.05 0.86 0.62–1.20 NS
Southern 2.33 1.74–3.13 < 0.001 2.67 1.94–3.69 < 0.001
Type of hospital
General hospital 1 1
University/teaching 1.30 1.03–1.64 < 0.05 1.29 0.99–1.70 NS (0.06)
Type of ICU
Medical ICU 1 1
Surgical ICU 0.75 0.45–1.24 NS 0.92 0.54–1.56 NS
Mixed ICU 0.61 0.40–0.92 < 0.05 0.73 0.47–1.13 NS
Other ICU 0.56 0.32–0.96 < 0.05 0.54 0.30–0.95 < 0.05
Number of beds in the ICU 1.01 1.00–1.02 NS
Years of clinical practice in ICU 1.00 0.99–1.01 NS
Number of yearly ICU admissions
≤ 300 1 1
301–600 0.76 0.56–1.01 NS 1.05 0.74–1.48 NS
601–1200 1.56 1.21–2.01 < 0.001 1.43 1.10–1.87 < 0.05
> 1200 0.90 0.73–1.11 NS 0.91 0.73–1.13 NS
Training status
ICU specialist 1
Other specialty 0.92 0.58–1.46 NS
Percentage of time dedicated to ICU 1.00 1.00–1.01 NS
External specialist consultation in case of difficult to treat infections
Consultation of external specialists 1
No consultation of external specialists 1.18 0.80–1.74 NS
Availability of protocols for empiric treatment in the ICU
Yes 1 1
No 1.79 1.36–2.35 < 0.001 1.59 1.19–2.13 < 0.05
Type of guidelines/protocols used for antimicrobial treatment
ICU-specific 1
Other (hospital-specific, national or international) 1.06 0.83–1.36 NS
None of these 1.40 0.63–3.12 NS
Availability of resistance statistics for the ICU
Regularly 1
Irregularly 1.19 0.89–1.61 NS
Not at all 1.04 0.67–1.63 NS
Do not know 0.71 0.44–1.16 NS
CI confidence interval; ICU intensive care unit; NS not significant, p > 0.05
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available in the future [30, 31]. The fact that “more
resources for infection control” was ranked third is en-
couraging, as this indicates that ICU physicians are
aware of the close relationship between cross-
transmission, ICU acquired-infections and antimicrobial
use and that AMR cannot be controlled without the im-
plementation of appropriate infection prevention and
control measures and the involvement of ICU physicians
in such activities. An interesting example of such in-
volvement is the control of carbapenem-resistant En-
terobacteriaceae in Israel by a national intervention [32].
“More opportunity for specialist consultation” was
ranked as the least preferred option, indicating that ICU
physicians (or at least the respondents to our survey)
have sufficient access to infectious disease specialists or
consider that their level of competence allows them to
manage antimicrobial treatment in severely ill patients.
The strength of this study is its relatively large num-
ber of responses from the target group of ICU physi-
cians who are prescribing antibiotics and its ability to
provide European sub-region-specific results. This sur-
vey has, however, several limitations. Firstly, the results
were based on a non-random sample of respondents
and a response rate could not be calculated. Given the
dissemination strategy, specific categories of ICUs or
ICU physicians, especially those with interest in AMR
may have been overrepresented. Secondly, we do not
know how many ICUs are represented by the respon-
dents as no information allowing the identification of
ICUs was collected to maintain the confidentiality of
respondents. Thirdly, grouping countries into four re-
gions may mask differences between countries and we
were not able to provide results by country due to dif-
ferences in the number of replies by country. Finally,
the main limitation is related to this study being based
on a survey asking for individual perception, which can-
not be verified or directly compared with epidemio-
logical studies.
Conclusions
This European survey clearly indicates that (a) European
ICU physicians are aware of the threat of AMR, (b) their
perception and experience is in line with quantitative
data collected in epidemiological studies, (c) infections
with bacteria resistant to almost all available antibiotics
are already a reality in ICUs in the EU/EEA, and (d) ac-
cess to last-line antibiotics is sometimes limited. Differ-
ences between European sub-regions emphasize the
need for national analysis and responses to the local
context. At the same time, multinational and multisec-
toral collaboration is needed to improve microbiological
diagnostics and access to antibiotics for ICU physicians,
who are on the frontline of the battle against AMR.
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